PKO Investment Management Joint Stock Co Has $375,000 Stock Position in IDEXX Laboratories, Inc. $IDXX

Key Points

• PKO Investment Management Joint Stock Co significantly reduced its holdings in IDEXX Laboratories, Inc. by 78.8% during the second quarter, ending with a position valued at $375,000.
• Insider selling has been notable, with executives Nimrata Hunt and Michael Lane selling shares and reducing their ownership stakes, indicating potential concerns about the stock's performance.
• IDEXX Laboratories reported strong earnings results, with an EPS of $3.63 for the last quarter, surpassing estimates, and set FY 2025 guidance of 12.400-12.760 EPS.

PKO Investment Management Joint Stock Co cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 78.8% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 700 shares of the company's stock after selling 2,600 shares during the quarter. PKO Investment Management Joint Stock Co's holdings in IDEXX Laboratories were worth $375,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sage Mountain Advisors LLC raised its stake in IDEXX Laboratories by 14.2% during the second quarter. Sage Mountain Advisors LLC now owns 725 shares of the company's stock worth $389,000 after acquiring an additional 90 shares in the last quarter. AlphaQuest LLC grew its holdings in shares of IDEXX Laboratories by 7.3% during the 2nd quarter. AlphaQuest LLC now owns 398 shares of the company's stock valued at $213,000 after purchasing an additional 27 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of IDEXX Laboratories by 1.3% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 201,918 shares of the company's stock valued at $108,297,000 after purchasing an additional 2,528 shares during the last quarter. Lazard Freres Gestion S.A.S. increased its position in IDEXX Laboratories by 11.9% during the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 90,904 shares of the company's stock worth $48,755,000 after purchasing an additional 9,671 shares in the last quarter. Finally, First Citizens Bank & Trust Co. lifted its stake in IDEXX Laboratories by 36.6% in the 2nd quarter. First Citizens Bank & Trust Co. now owns 19,851 shares of the company's stock valued at $10,647,000 after purchasing an additional 5,315 shares during the last quarter. Institutional investors own 87.84% of the company's stock.

Insiders Place Their Bets

In other news, EVP Nimrata Hunt sold 1,200 shares of the business's stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $656.53, for a total value of $787,836.00. Following the transaction, the executive vice president owned 16,807 shares in the company, valued at approximately $11,034,299.71. The trade was a 6.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael Lane sold 8,411 shares of the company's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $627.74, for a total transaction of $5,279,921.14. Following the completion of the sale, the executive vice president directly owned 7,132 shares in the company, valued at approximately $4,477,041.68. This represents a 54.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 54,057 shares of company stock valued at $34,293,468 over the last three months. Insiders own 0.98% of the company's stock.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of research reports. Jefferies Financial Group began coverage on shares of IDEXX Laboratories in a research note on Tuesday, July 1st. They set a "buy" rating and a $625.00 target price on the stock. Piper Sandler restated a "neutral" rating and set a $700.00 price objective (up previously from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. BTIG Research upped their target price on IDEXX Laboratories from $545.00 to $785.00 and gave the stock a "buy" rating in a report on Tuesday, August 5th. Stifel Nicolaus set a $640.00 target price on IDEXX Laboratories in a research report on Monday, August 4th. Finally, UBS Group began coverage on IDEXX Laboratories in a research note on Wednesday, October 1st. They set a "neutral" rating and a $720.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $656.50.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $640.85 on Friday. The company has a market capitalization of $51.27 billion, a price-to-earnings ratio of 53.36, a PEG ratio of 4.15 and a beta of 1.58. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $688.12. The stock has a fifty day simple moving average of $638.40 and a 200 day simple moving average of $559.16.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping the consensus estimate of $3.28 by $0.35. The firm had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business's quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.